Dr. Bayle is a creative scientist with 30 years of post-graduate experience in biotech and academia. His training in Oncology, Immunology and Developmental Biology, led to a focus on the development of innovative molecular switches to regulate protein activity for biological impact. This ultimately brought him to Bellicum Pharmaceuticals to develop innovative methods to regulate CAR-T and CAR-NK with small molecules yielding 2 IND in solid tumors. During his 9 years at Bellicum he led the Discovery Program and rose to VP of all Research.

After seeing first-hand the impact that engineered cell therapy can have on cancer treatment, Henri co-founded NKILT Therapeutics with Raphael Ognar with the purpose of making engineered cell therapy available to more patients across cancer indications.

Henri has a PhD in Molecular Biology from Princeton University and performed his post-doctoral work in Pathology at Stanford University School of Medicine. He was Assistant Professor of Physiology and Biophysics at Baylor College of Medicine prior to joining Bellicum.

Outside of his R&D activity, Henri enjoys repairing and remodeling old houses and automobiles as well as experimental cooking for his family, friends and neighbors.